LV11326B - Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof - Google Patents

Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof Download PDF

Info

Publication number
LV11326B
LV11326B LVP-96-85A LV960085A LV11326B LV 11326 B LV11326 B LV 11326B LV 960085 A LV960085 A LV 960085A LV 11326 B LV11326 B LV 11326B
Authority
LV
Latvia
Prior art keywords
acid
compound
temperature
composition
quot
Prior art date
Application number
LVP-96-85A
Other languages
English (en)
Latvian (lv)
Other versions
LV11326A (lv
Inventor
Roger Cherng Fu
De - Mei Leung
Jeffrey S Fleitman
Michele C Rizzolio
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of LV11326A publication Critical patent/LV11326A/xx
Publication of LV11326B publication Critical patent/LV11326B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
LVP-96-85A 1993-09-15 1996-03-15 Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof LV11326B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12184193A 1993-09-15 1993-09-15
PCT/US1994/010142 WO1995007902A1 (en) 1993-09-15 1994-09-12 Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof

Publications (2)

Publication Number Publication Date
LV11326A LV11326A (lv) 1996-06-20
LV11326B true LV11326B (en) 1996-10-20

Family

ID=22399119

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-96-85A LV11326B (en) 1993-09-15 1996-03-15 Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof

Country Status (31)

Country Link
US (2) US5543408A (lt)
EP (1) EP0724581B1 (lt)
JP (1) JP3411038B2 (lt)
KR (1) KR100349772B1 (lt)
CN (1) CN1060770C (lt)
AT (1) ATE173475T1 (lt)
AU (1) AU677435B2 (lt)
BR (1) BR9407469A (lt)
CA (1) CA2171836C (lt)
CZ (1) CZ292423B6 (lt)
DE (1) DE69414720T2 (lt)
DK (1) DK0724581T3 (lt)
ES (1) ES2123831T3 (lt)
FI (1) FI119639B (lt)
HU (1) HU217300B (lt)
IL (1) IL110970A (lt)
LT (1) LT4052B (lt)
LV (1) LV11326B (lt)
MX (1) MXPA94007099A (lt)
NO (1) NO314727B1 (lt)
NZ (1) NZ273801A (lt)
PH (1) PH30685A (lt)
PL (1) PL178522B1 (lt)
RO (2) RO118427B1 (lt)
RU (1) RU2132849C1 (lt)
SG (1) SG55006A1 (lt)
SI (1) SI9420052B (lt)
TW (1) TW370527B (lt)
UA (1) UA49797C2 (lt)
WO (1) WO1995007902A1 (lt)
ZA (1) ZA947088B (lt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
IN188985B (lt) * 1998-12-09 2002-11-30 Biocon Ltd
CZ292123B6 (cs) * 2001-06-08 2003-08-13 Ivax Pharmaceuticals S.R.O. Způsob přípravy mykofenolátu mofetilu
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
US20050187170A1 (en) * 2003-06-16 2005-08-25 Biocryst Pharmaceuticals, Inc. Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
ES2308226T3 (es) * 2003-09-11 2008-12-01 Sandoz Ag Proceso para la produccion de micofenolato mofetil.
US7683188B2 (en) * 2004-04-26 2010-03-23 TEVA Gyógyszergyár Zártkōrūen Mūkōdō Részvénytársaság Process for preparation of mycophenolic acid and ester derivatives thereof
MXPA06005658A (es) * 2004-04-27 2007-04-10 Teva Gyogyszergyar Zartkoruen Proceso para preparacion de micofenolato mofetil, y otros esteres de acido micofenolico.
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
US7439373B2 (en) * 2004-07-20 2008-10-21 TEVA Gyógyszergyár Zártkörúen Múködö Részvénytársaság Crystalline mycophenolate sodium
CN100383520C (zh) * 2004-09-20 2008-04-23 复旦大学 一种测定人血浆中霉酚酸及其代谢物的方法
US20060235070A1 (en) * 2005-02-08 2006-10-19 Hayden Michael R Compositions and methods for treating vascular, autoimmune, and inflammatory diseases
WO2006086498A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
US20080280977A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
PL2032521T3 (pl) 2006-06-27 2010-05-31 Sandoz Ag Nowy sposób wytwarzania soli
CN101953807A (zh) * 2010-10-09 2011-01-26 山西普德药业有限公司 一种注射用吗替麦考酚酯冻干粉针剂及其制备方法
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
CN105452213B (zh) 2013-03-14 2017-09-22 阿尔克梅斯制药爱尔兰有限公司 富马酸酯前体药物及其在治疗多种疾病中的应用
US9168246B2 (en) * 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
CA2940845C (en) 2014-02-24 2019-09-24 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
WO2018167628A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
EP3836898A2 (en) 2018-08-18 2021-06-23 FTF Pharma Private Limited Pharmaceutical suspension for oral dosage
CN117177749A (zh) 2021-03-03 2023-12-05 萨那生物科技公司 与心肌细胞疗法一起使用的免疫抑制疗法以及相关的方法和组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328213A (en) * 1979-11-28 1982-05-04 Schering Corporation Stable injectable labetalol formulation
US4478829A (en) * 1983-04-28 1984-10-23 Armour Pharmaceutical Company Pharmaceutical preparation containing purified fibronectin
SU1170760A1 (ru) * 1984-02-20 1996-09-20 Ф.Ю. Рачинский Дигидробромид 2-(2-морфолиноэтилтио)бензимидазола, повышающий физическую работоспособность и ускоряющий процессы восстановления после физических нагрузок и длительного стресса
US4753935A (en) 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
FR2653999A1 (fr) * 1989-11-06 1991-05-10 Adir Nouveaux derives de la morpholine, leur procede de preparation et les compositions pharmaceutiques les renfermant.

Also Published As

Publication number Publication date
FI119639B (fi) 2009-01-30
LT4052B (en) 1996-10-25
WO1995007902A1 (en) 1995-03-23
CN1060770C (zh) 2001-01-17
IL110970A0 (en) 1994-11-28
TW370527B (en) 1999-09-21
DE69414720T2 (de) 1999-04-08
MXPA94007099A (es) 2004-01-23
SI9420052B (sl) 2004-02-29
AU7723894A (en) 1995-04-03
ES2123831T3 (es) 1999-01-16
LT96028A (en) 1996-08-26
JPH09502721A (ja) 1997-03-18
NO961075D0 (no) 1996-03-15
HU9600652D0 (en) 1996-05-28
LV11326A (lv) 1996-06-20
HUT75119A (en) 1997-04-28
KR100349772B1 (ko) 2002-12-28
FI961169A0 (fi) 1996-03-13
ATE173475T1 (de) 1998-12-15
EP0724581B1 (en) 1998-11-18
US5543408A (en) 1996-08-06
RO118427B1 (ro) 2003-05-30
SG55006A1 (en) 1998-12-21
AU677435B2 (en) 1997-04-24
US5545637A (en) 1996-08-13
BR9407469A (pt) 1996-11-12
EP0724581A1 (en) 1996-08-07
PL313480A1 (en) 1996-07-08
DE69414720D1 (de) 1998-12-24
PH30685A (en) 1997-09-16
NO961075L (no) 1996-03-15
HU217300B (hu) 1999-12-28
NZ273801A (en) 1997-10-24
DK0724581T3 (da) 1999-08-02
CZ78896A3 (en) 1996-10-16
PL178522B1 (pl) 2000-05-31
NO314727B1 (no) 2003-05-12
CA2171836C (en) 2006-11-14
SI9420052A (en) 1996-12-31
UA49797C2 (uk) 2002-10-15
ZA947088B (en) 1996-03-14
CA2171836A1 (en) 1995-03-23
IL110970A (en) 1999-01-26
RO118075B1 (ro) 2003-01-30
JP3411038B2 (ja) 2003-05-26
CZ292423B6 (cs) 2003-09-17
HK1012624A1 (en) 1999-08-06
FI961169L (fi) 1996-03-13
RU2132849C1 (ru) 1999-07-10
CN1131420A (zh) 1996-09-18

Similar Documents

Publication Publication Date Title
EP0724581B1 (en) Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof
US9642853B2 (en) Stable pharmaceutical composition containing folates
JP6182262B2 (ja) 抗がん剤を含む安定な水溶性医薬組成物
JP4142149B2 (ja) バンコマイシンの凍結乾燥製剤
US9301922B1 (en) Stable high strength pharmaceutical composition of levoleucovorin
ES2657944T3 (es) Sal estable de arginina de pemetrexed y composiciones que la comprenden
WO2012013116A1 (zh) 含氨基酸稳定剂的替莫唑胺药物组合物及其制备方法
EP4658244A1 (en) Injectable composition, pharmaceutical formulation including the same, and method for preparing the composition
JP2001519390A (ja) 安定剤としてグリシンを含む製薬学的製剤
HK1012624B (en) Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof
US20070014875A1 (en) Novel drug delivery system for proton pump inhibitors and process thereof
CA2503087A1 (en) Intravenous formulations of pyridoxal 5'-phosphate and method of preparation
WO2024009319A1 (en) Liquid injectable compositions of trilaciclib
WO2025165852A1 (en) Liquid formulations of lurbinectedin
TW201302755A (zh) 含胺基酸穩定劑的替莫唑胺醫藥組成物及其製備方法
KR20060130933A (ko) 클로트리마졸 함유 직장 좌제 조성물